Literature DB >> 8853243

Orthotopic engraftment of human lung tumours in SCID mice for the study of metastasis.

R E Cuenca1, H Takita, R Bankert.   

Abstract

This study presents a new technique for the orthotopic engraftment of human lung tumours in SCID mice and demonstrates the importance of a more clinically relevant route of tumour propagation for the study of metastatic potential. The orthotopic engraftment of human lung tumour biopsy specimens was performed via an anterior thoracotomy into SCID mice. Engraftment of non-small cell lung cancer specimens from nine patients into 52 SCID mice yielded a 31% engraftment rate and a 50% metastasis rate. Unlike subcutaneous inoculation, the engraftment rates following the orthotopic inoculation did not vary between squamous cell carcinomas and adenocarcinomas. Direct visceral pleural invasion was seen in most cases. Orthotopically placed tumours grew 5-fold by 4 to 6 months. Unique to this model was the observation of metastasis to clinically relevant sites, such as the adrenal gland and supraclavicular lymph nodes. Contralateral lung metastases were also noted in 37.5%, and one ovarian metastasis occurred. The procedure was well tolerated, with survival rates of 98%.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8853243     DOI: 10.1016/s0960-7404(96)80005-3

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

1.  Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation.

Authors:  José Miguel Pardo-Sánchez; Nuria Mancheño; José Cerón; Carlos Jordá; Emilio Ansotegui; Óscar Juan; Sarai Palanca; Antonio Cremades; Carolina Gandía; Rosa Farràs
Journal:  Cancers (Basel)       Date:  2021-06-14       Impact factor: 6.639

2.  Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine.

Authors:  Katherine M Morgan; Gregory M Riedlinger; Jeffrey Rosenfeld; Shridar Ganesan; Sharon R Pine
Journal:  Front Oncol       Date:  2017-01-19       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.